Studying sputum inflammation in bronchiectasis
Part of Lungs & breathing clinical trials.
This study looks at how different types of inflammation in your sputum (mucus you cough up) relate to your lung health over time. It aims to understand why some people with bronchiectasis do better than others, which may help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have a body mass index (BMI) of at least 18 (you can check with your doctor).
- You need a CT scan showing bronchiectasis in at least one part of your lungs, and you must have typical symptoms like chronic cough, mucus, or occasional blood in your sputum.
- You must have had at least 2 lung flare-ups (sudden worsening of symptoms) in the past year.
- If you use long-acting inhalers (bronchodilators), your dose must have been stable for at least 3 months.
- You must be expected to live at least another year (your doctor can help with this).
- Women must be past menopause, have had surgery to prevent pregnancy, or use effective birth control. Men must use effective birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This study tests a new medicine for people with non-cystic fibrosis bronchiectasis. It aims to see if the drug can help reduce symptoms and improve quality of life.
This study looks at what factors are linked to flare-ups and serious outcomes in people with non–cystic fibrosis bronchiectasis. You may be followed because your lung scans and recent stability help researchers understand what predicts worsening.
This study helps doctors understand how severe your bronchiectasis is and predict when you might have flare-ups. You'll have routine tests over 12 months to help researchers learn more about this condition and improve future care.
This study helps doctors identify different types of bronchiectasis (a lung disease where airways are permanently widened and damaged) to better understand how the disease develops and progresses. By following patients over time and collecting medical information, researchers hope to create a system that predicts which patients will worsen and need different treatments.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
Hear when a new Non-cystic Fibrosis Bronchiectasis (NCFBE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.